论文部分内容阅读
目的观察利拉鲁肽治疗新诊断T2DM患者的临床疗效。方法 48例新诊断T2DM患者被随机分为利拉鲁肽组和二甲双胍组,每组各24例。结果治疗12周后,两组FPG、2hPG、HbA1c、体重、HOMA-IR及血脂等差异均有统计学意义(P<0.01),利拉鲁肽组优于二甲双胍组(P<0.05),且治疗后利拉鲁肽组FC-P、2hC-P水平升高(P<0.01)。结论利拉鲁肽用于治疗新诊断T2DM患者,安全有效。
Objective To observe the clinical efficacy of liraglutide in newly diagnosed T2DM patients. Methods 48 newly diagnosed T2DM patients were randomly divided into liraglutide group and metformin group, 24 cases in each group. Results After 12 weeks of treatment, the differences of FPG, 2hPG, HbA1c, body weight, HOMA-IR and blood lipid among the two groups were statistically significant (P <0.01), and the liraglutide group was superior to the metformin group After treatment, the levels of FC-P and 2hC-P in liraglutide group increased (P <0.01). Conclusion Liraglutide is safe and effective in the treatment of newly diagnosed T2DM patients.